Enliven Therapeutics (ELVN) Price & Analysis

Compare

305 Followers

ELVN Stock Chart & Stats

$19.64

$0.01(0.04%)

At close: Jan 08 4:00 PM EST

$19.64

$0.01(0.04%)

Day’s Range― - ―

52-Week Range$13.30 - $26.48

Previous CloseN/A

Volume37.78K

Average Volume (3M)550.98K

Market Cap

$1.13B

Enterprise Value$555.10M

Total Cash (Recent Filing)$490.50M

Total Debt (Recent Filing)$376.00K

Price to Earnings (P/E)―

Beta1.21

Next Earnings

Mar 12, 2026

EPS Estimate

-0.38

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.32

Shares Outstanding59,235,546

10 Day Avg. Volume465,629

30 Day Avg. Volume550,976

Financial Highlights & Ratios

PEG Ratio1.99

Price to Book (P/B)3.42

Price to Sales (P/S)0.00

P/FCF Ratio-14.46

Enterprise Value/Market Cap0.49

Enterprise Value/Revenue1.76K

Enterprise Value/Gross Profit-7.21K

Enterprise Value/Ebitda-5.16

Forecast

1Y Price Target

$41.00

Price Target Upside108.76% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsEnliven's data in heavily pre-treated patients is impressive, rapidly showing deep remissions.

Financial PerformanceEnliven recorded a net loss of $0.32 per share—narrower than the estimated net loss of $0.41 per share.

Market PositionELVN-001's impressive efficacy and favorable tolerability profile have either remained consistent or improved with longer follow-up and additional patients.

Bears Say

Market CompetitionDirect comparisons of data between Enliven and Terns' compounds are difficult due to differences in trial designs and patient eligibility.

Safety ConcernsKey long-term safety concerns for CML treatments include cardio, liver, and kidney toxicity.

Trial EnrollmentThe enrollment speed of Enliven's pivotal trial could be slowed by Terns likely initiating a Phase 3 trial with '701.

Enliven Therapeutics News

Enliven reports Q3 EPS (32c) vs. (48c) last year

As of September 30, the company had cash, cash equivalents and marketable securities totaling $477.6M, expected to provide...

3d ago

ELVN

Enliven being 20% down on Terns news ‘makes no sense,’ says Mizuho

Mizuho analyst Salim Syed notes that Terns Pharmaceuticals’ (TERN) TERN-701’s ASH abstract was released and while “there is...

13d ago

ELVN

TERN

Enliven, Novartis drugs poised to lead in CML markets, says Clear Street

After Novartis (NVS) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency...

30d ago

NVS

ELVN

Enliven Therapeutics: Strategic Advancements and Promising Clinical Progress Support Buy Rating

JonesTrading analyst Soumit Roy has maintained their bullish stance on ELVN stock, giving a Buy rating today. Soumit...

2d ago

ELVN

Enliven Therapeutics: Promising Financial Discipline and Strategic Positioning Justify Buy Rating

Enliven Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from...

2d ago

ELVN

Enliven Therapeutics Reports Q3 2025 Financial Results

Enliven Therapeutics, Inc. ( ($ELVN) ) has released its Q3 earnings. Here is a breakdown of the information...

3d ago

ELVN

Promising Future for Enliven Therapeutics: Buy Rating Backed by Strong Phase 1 Data and Financial Stability

Enliven Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from...

3d ago

ELVN

Enliven Therapeutics: Strategic Positioning and Promising Data Justify Buy Rating

JonesTrading analyst Soumit Roy has maintained their bullish stance on ELVN stock, giving a Buy rating yesterday. Soumit...

12d ago

ELVN

Promising Investment Opportunity: Enliven Therapeutics’ ELVN-001 Shows Strong Potential in CML Treatment

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Enliven Therapeutics and keeping the price target...

13d ago

ELVN

Enliven Therapeutics Advances in CML Treatment with ELVN-001 Study

Enliven Therapeutics, Inc. (($ELVN)) announced an update on their ongoing clinical study. Study Overview: Enliven Therapeutics, Inc. is...

20d ago

ELVN

Enliven Therapeutics’ ELVN-001: A Promising Phase 1 Study for Chronic Myeloid Leukemia

Enliven Therapeutics, Inc. (($ELVN)) announced an update on their ongoing clinical study. Enliven Therapeutics, Inc. is conducting a...

20d ago

ELVN

Enliven Therapeutics: Strong Buy Rating Backed by Promising Clinical Results and Robust Financial Position

JonesTrading analyst Soumit Roy has maintained their bullish stance on ELVN stock, giving a Buy rating today. Soumit...

3M ago

ELVN

Enliven Therapeutics: Strong Financial Foundation and Promising ELVN-001 Development Justify Buy Rating

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Enliven Therapeutics, with...

3M ago

ELVN

Enliven files automatic mixed securities shelf

17:01 EDT Enliven (ELVN) files automatic mixed securities shelf Published first on TheFly – the ultimate source for...

3M ago

ELVN

ELVN FAQ

What was Enliven Therapeutics’s price range in the past 12 months?

Enliven Therapeutics lowest stock price was $13.30 and its highest was $26.48 in the past 12 months.

What is Enliven Therapeutics’s market cap?

Enliven Therapeutics’s market cap is $1.13B.

When is Enliven Therapeutics’s upcoming earnings report date?

Enliven Therapeutics’s upcoming earnings report date is Mar 12, 2026 which is in 116 days.

How were Enliven Therapeutics’s earnings last quarter?

Enliven Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.433 by $0.113.

Is Enliven Therapeutics overvalued?

According to Wall Street analysts Enliven Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Enliven Therapeutics pay dividends?

Enliven Therapeutics does not currently pay dividends.

What is Enliven Therapeutics’s EPS estimate?

Enliven Therapeutics’s EPS estimate is -0.38.

How many shares outstanding does Enliven Therapeutics have?

Enliven Therapeutics has 59,235,546 shares outstanding.

What happened to Enliven Therapeutics’s price movement after its last earnings report?

Enliven Therapeutics reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.433. Following the earnings report the stock price went up 3.36%.

Which hedge fund is a major shareholder of Enliven Therapeutics?

Currently, no hedge funds are holding shares in ELVN

Enliven Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-25.43%

Trailing 12-Months

Asset Growth

54.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Enliven Therapeutics

Enliven Therapeutics (ELVN) is a biopharmaceutical company dedicated to discovering and developing innovative therapies for patients with serious diseases. The company operates in the healthcare sector, focusing on cutting-edge research and development to bring novel treatments to market. Enliven Therapeutics aims to address unmet medical needs through its pipeline of therapeutic candidates, leveraging advanced scientific approaches to improve patient outcomes.

Enliven Therapeutics (ELVN) Earnings & Revenues

Historic Earnings Reports

ELVN Stock 12 Month Forecast

Average Price Target

$41.00

▲(108.76% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","25":"$25","33":"$33","41":"$41","49":"$49"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$36.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,25,33,41,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.42,25.310769230769232,27.201538461538462,29.092307692307692,30.983076923076922,32.87384615384615,34.76461538461538,36.65538461538462,38.54615384615384,40.43692307692308,42.3276923076923,44.21846153846154,46.10923076923077,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.42,24.772307692307695,26.124615384615385,27.47692307692308,28.82923076923077,30.181538461538462,31.533846153846156,32.886153846153846,34.238461538461536,35.59076923076923,36.94307692307692,38.29538461538462,39.64769230769231,{"y":41,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.42,24.38769230769231,25.355384615384615,26.323076923076925,27.290769230769232,28.25846153846154,29.226153846153846,30.193846153846152,31.161538461538463,32.12923076923077,33.096923076923076,34.06461538461539,35.03230769230769,{"y":36,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.63,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.43,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.86,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.83,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.73,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.89,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.42,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >